A Medical Device Daily
Quanterix (Cambridge, Massachusetts), which refers to itself as "the leader in single-molecule protein detection," reported being awarded a Phase I Small Business Innovative Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health (NIH).
This grant supports development of the company's Single Molecule Array (SiMoA(TM)) technology to develop ultrasensitive assays for the detection of proteins implicated in cancer.
Nicholas Naclerio, chairman/CEO of Quanterix, said "Quanterix's platform will allow diseases to be detected at the earliest stages to increase the likelihood that treatments can alleviate or stabilize the disease process and help ensure positive patient outcomes. The application of this technology will provide medical researchers with an unprecedented tool for detecting low abundance biological molecules, and facilitate the development of a new generation of diagnostic products useful for early detection of diseases, including cancer."
David Duffy, senior director of platform technology and principal investigator for the grant, added, "This SBIR award recognizes the potential of SiMoA to measure low-abundance proteins in serum. Funding will be used to develop and validate assays and instrumentation that enable extremely high sensitivity measurements of cancer markers."